GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

luspatercept   Click here for help

GtoPdb Ligand ID: 10538

Synonyms: ACE-536 | ACE536 | luspatercept-aamt | Reblozyl®
Approved drug
luspatercept is an approved drug (FDA (2019), EMA (2020))
Compound class: Peptide
Comment: Luspatercept (ACE-536) is a fusion protein comprising human ACVR2B (activin receptor type 2B) extracellular domain (which is mutated to reduce activin binding), fused with human immunoglobulin G1 Fc fragment [2]. Luspatercept was initially proposed as a ligand trap for growth/differentiation factor-11 (GDF11; and other TGFβ family ligands). Mechanistically, it reduces Smad2/3 activation, and promotes maturation of late-stage erythroid precursors, independently of the erythropoietin (EPO) pathway. In contrast, erythropoietin stimulates proliferation of early-stage erythrocyte precursors.
Using Gdf11 knockout, Guerra et al. (2019) disputed GDF11 as an important molecular target of luspatercept and its proposed inhibitory effect on late erythropoiesis [1].
No information available.
Summary of Clinical Use Click here for help
Luspatercept (ACE-536) is used as an erythroid maturation agent. It was granted FDA approval in November 2019 as a treatment for adult patients with beta thalassemia-associated anemia who require regular red blood cell transfusions. European Union approval by the EMA was issued in June 2020, indicated for the treatment of anemia associated with beta thalassemia and myelodysplastic syndromes.